John Mark Awad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John Mark Awad has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Aisling Kelly
Precision Vaccines Program, Boston Children’s Hospital, Boston, USA
1 shared publicationBranden Lee
Precision Vaccines Program, Boston Children’s Hospital, Boston, USA
1 shared publication- Byron Brook
Precision Vaccines Program, Boston Children’s Hospital, Boston, USA
1 shared publication Cali Sweitzer
Precision Vaccines Program, Boston Children’s Hospital, Boston, USA
1 shared publicationChiwoo Oh
Precision Vaccines Program, Boston Children’s Hospital, Boston, USA
1 shared publicationConstance Marques-Mourlet
Precision Vaccines Program, Boston Children’s Hospital, Boston, USA
1 shared publication
Latest Publications
- Open Access
- 4 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Discovery of a small molecule TLR3 agonist adjuvant
Pattern-recognition receptor (PRR) agonists are valuable agents across multiple medical applications, from vaccinology to immune-oncology. However, well-defined and potent small molecule agonists for many PRRs still await discovery and development. Screening of chemical libraries of ~200,000 small molecules for maturation of human monocytic cells by quantifying NF-κB activation and cell adherence was completed. From this screen, we selected a thiazole benzamide derivative, PVP-057, for its robust immunomodulatory properties, low toxicity profile, and concentration-dependent activity. In vitro investigation of pathway and receptor activation reveals that PVP-057 is a Toll-like receptor 3 (TLR3) agonist. As a single-component adjuvant, administered intramuscularly or intradermally to female mice, PVP-057 enhances long-term humoral immunogenicity of varicella-zoster virus glycoprotein E to levels comparable to those induced by the clinical grade standard benchmark adjuvant, AS01B, while concurrently inducing cell-mediated immunity. To demonstrate the large-scale and precise synthesis necessary for the efficient mass production of a small molecule agonist, a green chemistry approach was completed, devising a three-step, 24-hour synthesis scheme for PVP-057, with a reliable purity of ~98%. Featuring highly efficient and scalable synthesis, a distinct TLR3-dependent mechanism of action, and robust adjuvanticity, the PVP-057 pharmacophore has prophylactic and therapeutic potential.
- 4 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDiscovery of a small molecule TLR3 agonist adjuvant
Pattern-recognition receptor (PRR) agonists are valuable agents across multiple medical applications, from vaccinology to immune-oncology. However, well-defined and potent small molecule agonists for many PRRs still await discovery and development. Screening of chemical libraries of ~200,000 small molecules for maturation of human monocytic cells by quantifying NF-κB activation and cell adherence was completed. From this screen, we selected a thiazole benzamide derivative, PVP-057, for its robust immunomodulatory properties, low toxicity profile, and concentration-dependent activity. In vitro investigation of pathway and receptor activation reveals that PVP-057 is a Toll-like receptor 3 (TLR3) agonist. As a single-component adjuvant, administered intramuscularly or intradermally to female mice, PVP-057 enhances long-term humoral immunogenicity of varicella-zoster virus glycoprotein E to levels comparable to those induced by the clinical grade standard benchmark adjuvant, AS01B, while concurrently inducing cell-mediated immunity. To demonstrate the large-scale and precise synthesis necessary for the efficient mass production of a small molecule agonist, a green chemistry approach was completed, devising a three-step, 24-hour synthesis scheme for PVP-057, with a reliable purity of ~98%. Featuring highly efficient and scalable synthesis, a distinct TLR3-dependent mechanism of action, and robust adjuvanticity, the PVP-057 pharmacophore has prophylactic and therapeutic potential.